Compare Stocks: HAE, DXCM, HQY, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$90.82 +1.7%	$79.21	$54.11 ▼ $92.59	$34.27B	1.41	5.48 million shs	2.55 million shs
HAE Haemonetics	$103.83 -1.1%	$84.89	$47.31 ▼ $109.57	$4.73B	0.52	889,158 shs	659,197 shs
HQY HealthEquity	$96.37 +3.2%	$98.16	$72.76 ▼ $107.62	$8.06B	0.21	781,766 shs	2.26 million shs
LNTH Lantheus	$100.77 +0.3%	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.15 million shs	1.14 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-1.65%	+21.84%	+23.16%	+18.91%
HAE Haemonetics	0.00%	-4.65%	+22.53%	+52.66%	+88.45%
HQY HealthEquity	0.00%	-8.58%	-4.55%	+9.52%	+9.54%
LNTH Lantheus	0.00%	+0.80%	-0.23%	+1.48%	+77.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$90.82 +1.7%	$79.21	$54.11 ▼ $92.59	$34.27B	1.41	5.48 million shs	2.55 million shs
HAE Haemonetics	$103.83 -1.1%	$84.89	$47.31 ▼ $109.57	$4.73B	0.52	889,158 shs	659,197 shs
HQY HealthEquity	$96.37 +3.2%	$98.16	$72.76 ▼ $107.62	$8.06B	0.21	781,766 shs	2.26 million shs
LNTH Lantheus	$100.77 +0.3%	$103.74	$49.67 ▼ $111.86	$6.58B	-0.03	2.15 million shs	1.14 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-1.65%	+21.84%	+23.16%	+18.91%
HAE Haemonetics	0.00%	-4.65%	+22.53%	+52.66%	+88.45%
HQY HealthEquity	0.00%	-8.58%	-4.55%	+9.52%	+9.54%
LNTH Lantheus	0.00%	+0.80%	-0.23%	+1.48%	+77.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.89	Moderate Buy	$88.71	-2.33% Downside
HAE Haemonetics	2.73	Moderate Buy	$97.56	-6.04% Downside
HQY HealthEquity	2.77	Moderate Buy	$110.93	15.11% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.29% Upside

Current Analyst Ratings Breakdown

Latest HAE, DXCM, HQY, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	HQY HealthEquity	Telsey Advisory Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/28/2026	HQY HealthEquity	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/28/2026	HQY HealthEquity	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/21/2026	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $119.00
8/19/2026	HAE Haemonetics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$95.00 ➝ $118.00
8/18/2026	HAE Haemonetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $110.00
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/11/2026	DXCM DexCom	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/11/2026	HAE Haemonetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.66B	7.35	$2.77 per share	32.80	$6.95 per share	13.07
HAE Haemonetics	$1.33B	3.54	$7.57 per share	13.72	$18.40 per share	5.64
HQY HealthEquity	$1.36B	5.91	$5.27 per share	18.27	$23.81 per share	4.05
LNTH Lantheus	$1.54B	4.27	$6.39 per share	15.78	$20.10 per share	5.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$836.30M	$2.53	35.90	29.49	1.53	20.12%	35.94%	14.75%	10/29/2026 (Estimated)
HAE Haemonetics	$97.31M	$2.04	50.90	18.12	2.08	7.12%	27.55%	9.65%	11/5/2026 (Estimated)
HQY HealthEquity	$215.20M	$2.77	34.79	21.18	1.62	17.36%	15.33%	9.51%	N/A
LNTH Lantheus	$233.56M	$4.14	24.34	18.63	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest HAE, DXCM, HQY, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2026	Q2 2027	HQY HealthEquity	$1.19	$1.24	+$0.05	$0.78	$349.22 million	$350.73 million
8/6/2026	Q1 2027	HAE Haemonetics	$1.08	$1.14	+$0.06	$0.72	$327.86 million	$339.38 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	DXCM DexCom	$0.6110	$0.70	+$0.0890	$0.64	$1.29 billion	$1.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
HQY HealthEquity	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.47	1.73	1.43
HAE Haemonetics	1.40	3.08	1.91
HQY HealthEquity	0.47	2.99	3.44
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
HAE Haemonetics	99.67%
HQY HealthEquity	99.55%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.28%
HAE Haemonetics	2.07%
HQY HealthEquity	1.60%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	11,000	377.36 million	376.30 million	Optionable
HAE Haemonetics	3,009	45.50 million	44.56 million	Optionable
HQY HealthEquity	2,814	83.60 million	82.26 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

HAE, DXCM, HQY, and LNTH Headlines

Recent News About These Companies

Penn Capital Management Company LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

August 30 at 6:08 AM | marketbeat.com

Cookson Peirce & Co. Inc. Takes $2.67 Million Position in Lantheus Holdings, Inc. $LNTH

August 30 at 4:24 AM | marketbeat.com

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

August 29 at 7:41 AM | businesswire.com

25,131 Shares in Lantheus Holdings, Inc. $LNTH Bought by Formula Growth Ltd.

August 28 at 4:16 AM | marketbeat.com

Summit Street Capital Management LLC Purchases New Holdings in Lantheus Holdings, Inc. $LNTH

August 27 at 5:52 AM | marketbeat.com

Curium acquisition of Lantheus backed by $5.375B of debt financing

August 26, 2026 | finance.yahoo.com

Jupiter Topco LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

August 26, 2026 | marketbeat.com

Expect Equity LLC Takes $3.56 Million Position in Lantheus Holdings, Inc. $LNTH

August 26, 2026 | marketbeat.com

Portland Investment Counsel Inc. Takes $2 Million Position in Lantheus Holdings, Inc. $LNTH

August 24, 2026 | marketbeat.com

232,597 Shares in Lantheus Holdings, Inc. $LNTH Acquired by William Blair Investment Management LLC

August 23, 2026 | marketbeat.com

39,362 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Heron Bay Capital Management

August 22, 2026 | marketbeat.com

Danske Bank A S Invests $6.41 Million in Lantheus Holdings, Inc. $LNTH

August 22, 2026 | marketbeat.com

Deutsche Bank AG Invests $27.60 Million in Lantheus Holdings, Inc. $LNTH

August 22, 2026 | marketbeat.com

Great Lakes Advisors LLC Takes Position in Lantheus Holdings, Inc. $LNTH

August 21, 2026 | marketbeat.com

Lantheus Holdings Inc

August 20, 2026 | money.usnews.com

Healthcare equipment and supplies stocks Q2 recap: Benchmarking Lantheus (NASDAQ:LNTH)

August 20, 2026 | msn.com

Rice Hall James & Associates LLC Purchases Shares of 43,735 Lantheus Holdings, Inc. $LNTH

August 18, 2026 | marketbeat.com

Chase Investment Counsel Corp Buys Shares of 20,000 Lantheus Holdings, Inc. $LNTH

August 17, 2026 | marketbeat.com

Empowered Funds LLC Takes $909,000 Position in Lantheus Holdings, Inc. $LNTH

August 17, 2026 | marketbeat.com

FDA approves Lantheus Imaging drug for Alzheimer's diagnostics

August 14, 2026 | msn.com

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

August 14, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HAE, DXCM, HQY, and LNTH Company Descriptions

DexCom NASDAQ:DXCM

$90.82 +1.53 (+1.71%)

As of 08/28/2026 04:00 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Haemonetics NYSE:HAE

$103.83 -1.17 (-1.11%)

As of 08/28/2026 03:58 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HealthEquity NASDAQ:HQY

$96.37 +2.98 (+3.19%)

As of 08/28/2026 04:00 PM Eastern

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Lantheus NASDAQ:LNTH

$100.77 +0.30 (+0.30%)

As of 08/28/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HAE, DXCM, HQY, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HAE, DXCM, HQY, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HAE, DXCM, HQY, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HAE, DXCM, HQY, and LNTH Company Descriptions

DexCom NASDAQ:DXCM

Haemonetics NYSE:HAE

HealthEquity NASDAQ:HQY

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HAE, DXCM, HQY, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HAE, DXCM, HQY, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HAE, DXCM, HQY, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HAE, DXCM, HQY, and LNTH Company Descriptions

DexCom NASDAQ:DXCM

Haemonetics NYSE:HAE

HealthEquity NASDAQ:HQY

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools